文献速递前列腺癌

AR-V7细胞质与细胞核定位对mCRPC患者ARPI获益的预测价值(PROPHECY试验)

Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).
PubMed 文献 · Prostate Cancer Prostatic Dis · 2026-04-02

该探索性研究分析PROPHECY试验中107例ARPI治疗前mCRPC患者的基线血样,用Epic平台检测CTC中AR-V7的核与细胞质定位。结果显示细胞质仅阳性AR-V7比核阳性更常见,且与较差PFS相关、PSA和OS结局居中,提示同时评估核与细胞质AR-V7可改善风险分层。

要点

  • 基线24%患者AR-V7阳性,其中细胞质仅阳性14%、核阳性10%。
  • 核阳性AR-V7患者PSA50应答率0%,细胞质仅阳性13%,AR-V7阴性30%。
  • 细胞质AR-V7阳性者PFS和OS差于AR-V7阴性,但PFS与核阳性者相似。

核心结论

  • 细胞质仅阳性AR-V7在mCRPC中比核AR-V7更常见,且与较差PFS和居中PSA、OS结局相关。
  • 同时评估CTC中核与细胞质AR-V7可能改善ARPI治疗前风险分层。

研究设计与样本

  • PROPHECY试验(NCT02269982)探索性分析,纳入107/118例ARPI治疗前mCRPC患者基线血样。
  • 使用Epic的CTC平台检测核与细胞质AR-V7,分析其与PSA50应答、OS和PFS的关联。

主要发现

  • 基线时10%(11/107)为核定位AR-V7,14%(15/107)为细胞质仅阳性AR-V7,合计24% AR-V7阳性。
  • 所有核AR-V7病例均显示AR过表达,而细胞质仅阳性病例中67%显示AR过表达。
  • PSA50应答率在核阳性、细胞质仅阳性和AR-V7阴性患者中分别为0%、13%和30%。
  • 细胞质AR-V7阳性患者PFS和OS差于AR-V7阴性患者,但PFS与核AR-V7阳性患者相似。

临床怎么用

  • 在ARPI治疗前评估CTC中核与细胞质AR-V7 fractions,可能识别PFS较差的患者。
  • 细胞质AR-V7检测可扩展AR-V7阳性定义,辅助避免无效ARPI治疗并个体化治疗决策。

局限性

  • 本研究为探索性分析,样本量有限(107例),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen receptor splice variant-7 (AR-V7), a constitutively active truncated protein, is linked to hormone therapy resistance. Nuclear AR-V7 in CTCs correlates with poor response and shorter progression-free survival (PFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) treated with ARPIs. The predictive value of cytoplasmic AR-V7 localization remains unclear. This exploratory study evaluated whether an AR-V7-agnostic CTC scoring criterion, including cytoplasmic detection, better predicts ARPI in this mCRPC setting. METHODS: Baseline blood from 107/118 pre-ARPI mCRPC patients in the PROPHECY trial (NCT02269982) was analyzed for nuclear and cytoplasmic AR-V7 using Epic's CTC platform. Associations with confirmed PSA50 response, OS, and PFS with abiraterone or enzalutamide treatment were examined. Correlations between AR overexpression, AR-V7 localization, and AR-V7 mRNA levels were assessed. Proportional hazards models adjusted for Halabi risk score and CellSearch CTC count (>5) evaluated cytoplasmic AR-V7 prognostic significance. RESULTS: At baseline, 10% (11/107) had nuclear-localized AR-V7 and 14% (15/107) had cytoplasmic-only AR-V7, totaling 24% AR-V7-positive. All nuclear AR-V7 cases showed AR overexpression vs. 67% of cytoplasmic-only cases. PSA50 responses occurred in 0% nuclear, 13% cytoplasmic-only, and 30% AR-V7-negative patients. Cytoplasmic AR-V7+ patients had worse PFS and OS than AR-V7- patients, but similar PFS compared with nuclear AR-V7 + , despite numerically better PSA declines and OS. CONCLUSIONS: Cytoplasmic-only AR-V7 is more prevalent than nuclear AR-V7 in mCRPC and is associated with poor PFS and intermediate PSA and OS outcomes. Assessing both nuclear and cytoplasmic AR-V7 in CTCs may improve risk stratification before ARPI therapy. CLINICAL SIGNIFICANCE: This study clarifies the clinical relevance of cytoplasmic AR-V7 in circulating tumor cells from men with metastatic castration-resistant prostate cancer. While nuclear-localized AR-V7 predicts extremely poor response, PFS, and overall survival with AR pathway inhibitors, cytoplasmic AR-V7 expands the definition of AR-V7-positive status and identifies patients with equally poor PFS and intermediate response and overall survival outcomes. Assessing both nuclear and cytoplasmic AR-V7 fractions may thus improve risk stratification heterogeneity and could better guide poor-risk ARPI treatment decisions by avoiding ineffective ARPI treatment, helping personalize therapy, and improving outcomes in men with mCRPC.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Gupta S, Guo S, Halabi S, et al. Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial). Prostate Cancer Prostatic Dis. 2026. PMID: 41922546. doi:10.1038/s41391-026-01113-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。